

- 1.126
- a) an effective dosage of a GLP-1 peptide agonist; and
 - b) an effective dosage of pioglitazone or rosiglitazone.

2.24
23. (new) The method of Claim ~~23~~¹ wherein an effective dosage of pioglitazone is administered.

3.25
24. (new) The method of Claim ~~24~~¹ wherein an effective dosage of rosiglitazone is administered.

4.26
25. (new) The method of Claim ~~25~~¹ wherein the GLP-1 agonist is a GLP-1 molecule.

5.27
26. (new) The method of Claim ~~26~~⁴ wherein the GLP-1 molecule is an analog of SEQ ID NO:1.

11.28
27. (new) The method of Claim ~~27~~⁴ wherein the GLP-1 molecule is a GLP-1 derivative.

17.29
28. (new) The method of Claim ~~28~~⁴ wherein the GLP-1 molecule comprises Valine, Glycine, Threonine, or Methionine at position 8.

28.30
29. (new) The method of Claim ~~29~~¹ wherein the effective dosage of the GLP-1 agonist is in the range of about 5 to about 200 µg per day.

23.31
30. (new) The method of Claim ~~30~~⁴ wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 µg per day.

6.32
31. (new) The method of Claim ~~31~~⁵ wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 µg per day.

12-32
32. (new) The method of Claim *11* ~~28~~ wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 µg per day.

18-33
33. (new) The method of Claim *17* ~~29~~ wherein the effective dosage of the GLP-1 molecule is in the range of about 5 to about 200 µg per day.

21-34
34. (new) The method of Claim *1* ~~23~~ wherein the effective dosage of the GLP-1 agonist is in the range of about 20 to about 100 µg per day.

24-35
35. (new) The method of Claim *4* ~~25~~ wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 µg per day.

7-36
36. (new) The method of Claim *5* ~~27~~ wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 µg per day.

13-37
37. (new) The method of Claim *11* ~~28~~ wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 µg per day.

19-38
38. (new) The method of Claim *17* ~~29~~ wherein the effective dosage of the GLP-1 molecule is in the range of about 20 to about 100 µg per day.

30-39
39. (new) The method of Claim *1* ~~23~~ wherein the effective dosage of the GLP-1 agonist is in the range of about 30 to about 50 µg per day.

Cont
A1
25 ~~41~~ 40. (new) The method of Claim ~~26~~⁴ wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.

8 ~~42~~ 41. (new) The method of Claim ~~27~~⁵ wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.

14 ~~43~~ 42. (new) The method of Claim ~~28~~¹¹ wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.

20 ~~44~~ 43. (new) The method of Claim ~~29~~¹⁷ wherein the effective dosage of the GLP-1 molecule is in the range of about 30 to about 50 µg per day.

31 ~~45~~ 44. (new) The method of Claim ~~30~~¹ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.

26 ~~46~~ 45. (new) The method of Claim ~~31~~⁴ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.

9 ~~47~~ 46. (new) The method of Claim ~~32~~⁵ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.

15 ~~48~~ 47. (new) The method of Claim ~~33~~¹¹ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.

21 ~~49~~ 48. (new) The method of Claim ~~34~~¹⁷ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 0.1 mg to about 200 mg per day.

3250
49. (new) The method of Claim ~~23~~⁴ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.

2751
50. (new) The method of Claim ~~23~~⁴ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.

1052
51. (new) The method of Claim ~~23~~⁵ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.

1653
52. (new) The method of Claim ~~23~~¹¹ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.

2254
53. (new) The method of Claim ~~23~~¹⁷ wherein the effective dosage of pioglitazone or rosiglitazone is in the range of about 50 mg to about 200 mg per day.

3355
54. (new) The method of Claim ~~23~~¹ wherein the GLP-1 agonist is administered as a composition comprising a GLP-1 molecule at a concentration of between 10^{-12} M and 10^{-5} M.

3456
55. (new) The method of Claim ~~23~~¹ wherein the GLP-1 agonist is administered as a controlled release preparation.

Remarks

New claims 23 through 56 have support throughout the Specification. For example, GLP-1 agonists, GLP-1 analogs, and GLP-1 derivatives are discussed on page 8, line 3 and beginning on page 10, line 29 through page 13. GLP-1 molecules with substitutions at position 8 which is actually the second amino acid of a mature peptide are disclosed in